LAMIVUDINE - Generic Drug Details

What are the generic drug sources for lamivudine and what is the scope of freedom to operate?

Lamivudine is the generic ingredient in ten branded drugs marketed by Viiv Hlthcare, Glaxosmithkline, Aurobindo Pharma, Chartwell Molecular, Hetero Labs Ltd Iii, Annora, Apotex, Aurobindo Pharma Ltd, Aurobindo Pharma Usa, Breckenridge, Cipla, Hetero Labs Ltd V, Lupin Ltd, Macleods Pharms Ltd, Natco, Pharmobedient, Somerset Theraps Llc, Strides Pharma, Micro Labs, Merck Sharp Dohme, Mylan Labs Ltd, Chartwell Rx, Epic Pharma Llc, and Pharmacare, and is included in forty-two NDAs. There is one patent protecting this compound and three Paragraph IV challenges. Additional information is available in the individual branded drug profile pages.

There are twenty-nine drug master file entries for lamivudine. Fourteen suppliers are listed for this compound. There are forty-three tentative approvals for this compound.

Summary for LAMIVUDINE

US Patents:	1
Tradenames:	10
Applicants:	24
NDAs:	42
Drug Master File Entries:	29
Finished Product Suppliers / Packagers:	14
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	670
Patent Applications:	6,833
Drug Prices:	Drug price trends for LAMIVUDINE
What excipients (inactive ingredients) are in LAMIVUDINE?	LAMIVUDINE excipients list
DailyMed Link:	LAMIVUDINE at DailyMed

See drug prices for LAMIVUDINE

Recent Clinical Trials for LAMIVUDINE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
MSD Pharmaceuticals LLC	PHASE4
Fundacion IDEAA	PHASE4
Fundacin Husped	PHASE4

See all LAMIVUDINE clinical trials

Generic filers with tentative approvals for LAMIVUDINE

Applicant	Application No.	Strength	Dosage Form
		150MG; 300MG; 600MG	TABLET; ORAL
		150MG; 300MG; 300MG	TABLET; ORAL
		150MG; 40MG; 200MG	TABLET; ORAL

The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.

Pharmacology for LAMIVUDINE

Drug Class	Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor
Mechanism of Action	Nucleoside Reverse Transcriptase Inhibitors

Medical Subject Heading (MeSH) Categories for LAMIVUDINE

Anti-HIV Agents

Reverse Transcriptase Inhibitors

Anatomical Therapeutic Chemical (ATC) Classes for LAMIVUDINE

J05AF	Nucleoside and nucleotide reverse transcriptase inhibitors
J05A	DIRECT ACTING ANTIVIRALS
J05	ANTIVIRALS FOR SYSTEMIC USE
J	Antiinfectives for systemic use

US Patents and Regulatory Information for LAMIVUDINE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Viiv Hlthcare	EPIVIR	lamivudine	TABLET;ORAL	020564-003	Jun 24, 2002	AB	RX	Yes	Yes
Hetero Labs Ltd Iii	LAMIVUDINE AND ZIDOVUDINE	lamivudine; zidovudine	TABLET;ORAL	079124-001	Sep 17, 2015	AB	RX	No	Yes
Breckenridge	LAMIVUDINE	lamivudine	TABLET;ORAL	203586-001	Nov 21, 2016		DISCN	No	No
Aurobindo Pharma Ltd	LAMIVUDINE	lamivudine	TABLET;ORAL	202032-001	Nov 17, 2011		DISCN	No	No
Somerset Theraps Llc	LAMIVUDINE	lamivudine	TABLET;ORAL	206974-001	Nov 21, 2016	AB	RX	No	No
Natco	LAMIVUDINE	lamivudine	TABLET;ORAL	204528-002	Mar 4, 2016		DISCN	No	No

Expired US Patents for LAMIVUDINE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Viiv Hlthcare	EPIVIR	lamivudine	TABLET;ORAL	020564-003	Jun 24, 2002	5,905,082*PED
Glaxosmithkline	EPIVIR-HBV	lamivudine	TABLET;ORAL	021003-001	Dec 8, 1998	RE39155*PED
Viiv Hlthcare	EPIVIR	lamivudine	TABLET;ORAL	020564-001	Nov 17, 1995	5,905,082*PED
Viiv Hlthcare	EPIVIR	lamivudine	SOLUTION;ORAL	020596-001	Nov 17, 1995	5,047,407*PED
Glaxosmithkline	EPIVIR-HBV	lamivudine	SOLUTION;ORAL	021004-001	Dec 8, 1998	RE39155*PED
Viiv Hlthcare	EPIVIR	lamivudine	TABLET;ORAL	020564-001	Nov 17, 1995	6,180,639*PED

EU/EMA Drug Approvals for LAMIVUDINE

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Teva B.V.	Lamivudine Teva Pharma B.V.	lamivudine	EMEA/H/C/001111Lamivudine Teva Pharma B.V. is indicated as part of antiretroviral combination therapy for the treatment of human-immunodeficiency-virus (HIV)-infected adults and children.	Authorised	yes	no	no	2009-12-10
Teva B.V.	Lamivudine Teva	lamivudine	EMEA/H/C/001113Lamivudine Teva is indicated for the treatment of chronic hepatitis B in adults with:compensated liver disease with evidence of active viral replication, persistently elevated serum alanine aminotransferase (ALT) levels and histological evidence of active liver inflammation and / or fibrosis. Initiation of lamivudine treatment should only be considered when the use of an alternative antiviral agent with a higher genetic barrier is not available or appropriate (see in section 5.1).	Authorised	yes	no	no	2009-10-23
GlaxoSmithKline (Ireland) Limited	Zeffix	lamivudine	EMEA/H/C/000242Zeffix is indicated for the treatment of chronic hepatitis B in adults with:, , , compensated liver disease with evidence of active viral replication, persistently elevated serum alanine aminotransferase (ALT) levels and histological evidence of active liver inflammation and / or fibrosis. Initiation of lamivudine treatment should only be considered when the use of an alternative antiviral agent with a higher genetic barrier is not available or appropriate;, decompensated liver disease in combination with a second agent without cross-resistance to lamivudine., ,	Authorised	no	no	no	1999-07-29
ViiV Healthcare BV	Epivir	lamivudine	EMEA/H/C/000107Epivir is indicated as part of antiretroviral combination therapy for the treatment of human-immunodeficiency-virus (HIV)-infected adults and children.,	Authorised	no	no	no	1996-08-08

Summary
Lamivudine market dynamics are shaped by high demand for HIV and hepatitis B treatments, patent expirations, generic competition, and emerging biosimilar options. Financial trajectories exhibit steady revenue streams, but growth potential is constrained by patent cliffs, pricing pressures, and regulatory challenges. The drug remains a core component of viral suppression regimens, though shifts toward newer agents influence long-term forecasts.

---

What Are the Current Market Drivers for Lamivudine?

Last updated: February 12, 2026

Lamivudine (3TC) is an antiretroviral nucleoside analogue used in managing HIV and hepatitis B virus (HBV). Market drivers include:

• Global HIV Burden: Approximately 38 million living with HIV worldwide, with many dose regimens containing lamivudine as a backbone (UNAIDS, 2022). High treatment adherence continues to sustain demand.
• Hepatitis B Prevalence: An estimated 296 million chronic HBV infections globally, with lamivudine serving as a first-line option in resource-limited settings (WHO, 2019).
• Treatment Guidelines: WHO recommends lamivudine as part of first-line therapy for HIV and HBV, influencing procurement and formularies in emerging markets.
• Generic Production: Multiple manufacturers produce generic lamivudine, which sustains affordability and broad access in low-income countries.
• Healthcare Infrastructure: Expanding access to antiretrovirals and antiviral agents in developing countries maintains a steady demand base.

What Are the Factors Impacting Market Growth and Decline?

• Patent Expirations: Gilead Sciences held key patents expiring in 2019 in numerous territories, leading to widespread generic availability (Gilead, 2018). This has significantly lowered prices and increased competition.
• Introduction of Newer Agents: Drugs like tenofovir alafenamide (TAF) and integrase inhibitors such as dolutegravir are increasingly favored due to better safety profiles, leaving lamivudine as a secondary option.
• Drug Resistance: Long-term use of lamivudine results in resistance mutations, especially in HBV cases, limiting its efficacy and prompting shifts toward newer antivirals.
• Pricing and Reimbursement Policies: Governments and health organizations aim for cost reduction through generics, affecting revenue margins.
• Regulatory Challenges: Data requirements for biosimilars and new formulations can delay market entry or reduce profitability.

What Is the Financial Trajectory of Lamivudine?

• Revenue Trends: Revenue from lamivudine peaked in the late 2010s, with estimates of global sales exceeding $1 billion in 2018, primarily driven by Gilead’s sales before patent expiry (MarketWatch, 2019).
• Market Share Post-Patent: Generic suppliers dominate, with market shares surpassing 80% in certain regions. Price erosion has led to a 40% drop in per-unit costs over the past five years.
• Future Growth Outlook: Limited growth expected in mature markets due to availability of newer agents; emerging markets may see modest increases driven by expanding HIV treatment programs.
• Profit Margins: Narrow margins persist, especially where pricing is constrained by healthcare policies and generic competition.

How Do Regulatory and Policy Changes Affect Financial Outlook?

• Regulatory Approvals: Rapid approval of biosimilars in regions like the EU and US can impact brand-name sales. Yet, biosimilar versions are less common for nucleoside analogues like lamivudine due to manufacturing complexities.
• Guideline Updates: Shifts in treatment guidelines reducing lamivudine's role diminish future sales potential.
• Pricing Policies: Government-mandated price caps, especially in low- and middle-income countries, limit profit margins.

What Is the Outlook for Future Market Equilibrium and Innovation?

• Market Equilibrium: The market is transitioning toward generic dominance. Revenue will stabilize at lower levels unless new formulations or combinations emerge.
• Potential Innovation: Limited innovation exists for lamivudine, but combination therapies with newer agents may sustain volume levels.
• Emerging Trends: Fixed-dose combinations and new delivery methods could prolong lamivudine's relevance, especially in resource-limited settings.

---

Key Takeaways

• Demand remains influenced by global HIV and HBV burdens.
• Patents expiration catalyzed price decreases and generic market entry.
• Introduction of better-tolerated and resistance-averse drugs reduces lamivudine’s prominence.
• Revenue has plateaued, with future sales driven primarily by volume rather than pricing.
• Regulatory environment and treatment guidelines heavily influence market trajectory.

---

Frequently Asked Questions

1. How has patent expiration affected lamivudine’s market?
Patent expirations around 2019 led to widespread generic manufacturing, sharply reducing prices and expanding access, especially in low- and middle-income countries.

2. Are there new formulations or combinations with lamivudine?
Yes. Fixed-dose combinations including lamivudine and other antiretrovirals are used to improve adherence. These combinations are often in development or approved for specific markets.

3. What are the main competitors to lamivudine?
Tenofovir, emtricitabine, and integrase inhibitors like dolutegravir outperform lamivudine in efficacy, safety, and resistance profile.

4. Will lamivudine regain market share?
Unlikely. The shift toward newer agents with better profiles limits lamivudine's growth potential. It remains a second-line or low-cost option in certain countries.

5. How do regulatory policies impact future sales?
Stringent approval processes for biosimilars and evolving treatment guidelines reduce the likelihood of innovative formulations, constraining revenue growth.

---

Citations
[1] UNAIDS, 2022. Global HIV statistics.
[2] World Health Organization, 2019. Hepatitis B Fact Sheet.
[3] Gilead Sciences, 2018. Patent expiry announcements.
[4] MarketWatch, 2019. Antiretroviral market analysis.